BMO Capital Maintains Outperform on Sarepta Therapeutics, Maintains $170 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $170 price target.
June 14, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on Sarepta Therapeutics with a $170 price target, indicating confidence in the company's future performance.
The reaffirmation of an Outperform rating and a $170 price target by BMO Capital suggests strong confidence in Sarepta Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100